Provided by Tiger Fintech (Singapore) Pte. Ltd.

Axsome Therapeutics

103.59
-2.9500-2.77%
Post-market: 103.920.3300+0.32%19:40 EDT
Volume:922.00K
Turnover:95.40M
Market Cap:5.11B
PE:-17.95
High:106.99
Open:106.12
Low:102.33
Close:106.54
Loading ...

Axsome Therapeutics’ Earnings Call Highlights Robust Growth

TIPRANKS
·
3 hours ago

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

Benzinga
·
10 hours ago

RBC Capital Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

TIPRANKS
·
12 hours ago

RBC Raises Price Target on Axsome Therapeutics to $189 From $184, Keeps Outperform Rating

MT Newswires Live
·
Yesterday

Wells Fargo Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

TIPRANKS
·
Yesterday

U.S. RESEARCH ROUNDUP- Axon Enterprise, Berkshire Hathaway, Idexx Laboratories

Reuters
·
Yesterday

Axsome Therapeutics: Strong Sales Performance and Strategic Growth Initiatives Drive Buy Rating

TIPRANKS
·
Yesterday

Optimistic Outlook for Axsome Therapeutics: Strong Financial Performance and Growth Potential Justify Buy Rating

TIPRANKS
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE-Tyson Foods, BioNTech, Gold miners

Reuters
·
04 Aug

Axsome Therapeutics Shares up 5.8% After Q2 Revenue Beats Estimates

THOMSON REUTERS
·
04 Aug

BUZZ-U.S. STOCKS ON THE MOVE-Axsome Therapeutics, Wayfair, IDEXX Laboratories

Reuters
·
04 Aug

Axsome Therapeutics Reports Strong Q2 2025 Performance

TIPRANKS
·
04 Aug

BUZZ-Axsome Therapeutics rises after Q2 revenue beat

Reuters
·
04 Aug

Axsome Therapeutics Shares up 5.1% Premarket After Co Posts Higher Q2 Revenue

THOMSON REUTERS
·
04 Aug

Axsome Therapeutics Q2 Net Income USD -47.973 Million

Reuters
·
04 Aug

Earnings Flash (AXSM) Axsome Therapeutics Posts Q2 Net Loss $0.97 a Share, vs. FactSet Est of $1.13 Loss

MT Newswires Live
·
04 Aug

Axsome Therapeutics Q2 Adj. EPS $(0.47) Beats $(1.07) Estimate, Sales $150.04M Beat $140.33M Estimate

Benzinga
·
04 Aug

Axsome Therapeutics Q2 EPS USD -0.97

THOMSON REUTERS
·
04 Aug

Axsome Therapeutics Inc: Current Cash Sufficient to Fund Anticipated Operations Into Cash Flow Positivity, Based on Current Operating Plan

THOMSON REUTERS
·
04 Aug

Axsome Therapeutics Q2 Operating Expenses USD 186.756 Million

THOMSON REUTERS
·
04 Aug